诺和诺德新一代减肥药Amycretin小型试验取得积极成果

Core Insights - Novo Nordisk's experimental drug Amycretin shows promising results in early trials, helping overweight and obese adults lose up to 24% of their body weight [1] - The company plans to initiate late-stage studies next year [1] - The primary side effects of the drug are gastrointestinal symptoms, with incidence rates comparable to other recent weight loss medications [1]